Tags: Drug.
JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman’s team as a hybrid between the dibenzopyran classical cannabinoid drugs and the novel indole derivatives in an attempt to unravel the differences in their binding modes to the CB1 receptor. While retaining structural elements from both families JWH-161 has a CB1 Ki of 19.0nM although it was found to be slightly weaker than THC in animal tests.
